Graph not available
Graph not available

Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Lyka Labs Ltd Performance

Today's Low
112.50
arrowIcon
Today's High
116.75
52 Wk Low
88.50
arrowIcon
52 Wk High
144.30


Open

116.75

Traded Value (Cr)

49.01 L

Prev. Close

114.5

VWAP

116.18

Volume

61,848

Face Value

10

Lyka Labs Ltd Fundamentals

Market Cap
₹ 392 Cr
P/E Ratio (TTM)
0.00
P/B Ratio
5.76
Debt to Equity
0.79
ROE
-12.34 %
EPS (TTM)
0.00
Dividend Yield
0.00%
Book Value
20.62

Click here to know more about Fundamentals

Lyka Labs Ltd Financials

Lyka Labs Ltd Financials

Lyka Labs Ltd Shareholding Pattern

Held By Apr 2024 Mar 2024 Dec 2023 Sep 2023
Promoters 58.10 % 54.81 % 54.81 % 54.81 %
Retail 31.48 % 33.90 % 34.32 % 35.49 %
Others 10.25 % 11.10 % 10.69 % 9.51 %
FII 0.16 % 0.17 % 0.17 % 0.18 %
Mutual Funds 0.01 % 0.01 % 0.01 % 0.01 %

Promoters

58.10%

Retail

31.48%

Others

10.25%

FII

0.16%

Mutual Funds

0.01%

Promoters

54.81%

Retail

33.90%

Others

11.10%

FII

0.17%

Mutual Funds

0.01%

Promoters

54.81%

Retail

34.32%

Others

10.69%

FII

0.17%

Mutual Funds

0.01%

Promoters

54.81%

Retail

35.49%

Others

9.51%

FII

0.18%

Mutual Funds

0.01%

Resistance and Support

₹117.52

PIVOT

resistance-arrow
Resistance
First Resistance₹119.533
Second Resistance₹122.467
Third Resistance₹124.483
support-arrow
Support
First Resistance₹114.583
Second Resistance₹112.567
Third Resistance₹109.633
RSI23.713
MACD-3.401
ADX30.803
CCI-148.693

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day61,84844,94772.67
Week60,48240,76066.78
1 Month97,04753,77463.08
6 Months41,71625,68061.56

About Lyka Labs Ltd

Initially manufacturing formulations, Lyka Labs brought bulk drugs into its operational fold by amalgamating Lyphin Chemicals Pvt Ltd with itself in Apr. '83. It also added a range of ayurvedic and animal health care products over the years. In 1990, it diversified into marketing medical and diagnostic equipment and instruments of Bekton Dickinson, US; Airsep Corporation, US; Coloplast, Denmark; and Terumo Corporation, Japan. Lyka Exports is the subsidiary of the company. The company offers a broad range of antibiotics used as life-savers and to treat minor infections. It has a fairly widespread product base with tropical steroids for skin disorders, anti-cancer products, cardio-vascular drugs and anti-inflammatory products. Lyka introduced, in India, cough lozenges containing dextromethorphan hydrobromide (DMR), favoured internationally as an effective and safe cough suppressant. Lyka has two formulations division and a bulk drugs division. It also set up additional manufacturing facilities for ointments. As part of its diversification, it has invested in Relic Finance, a company carrying on the business of finance and merchant banking. A GOI-recognised Export House, it received the Certificate of Merit for its excellent export performance in 1993-94. In the same year, it received an award from CHEMEXCIL for its outstanding performance. During 1997-98, the company's administrative office & plant at tarapur has been awarded ISO 9002 certification for its quality management system by SGS Yarsley International Certification Services Limited, UK. The production carried out at Bombay has been shifted to Tarapur and Ankleshwar in the year 1999-2000, inorder to achieve economies of scale and better compliance. The company has assigned Trade Marks and transferred technical, marketing know-how and allied rights pertaining to some of its products. The Company's factory at Tarapur, re-commissioned production in March, 2013. It launched Glutathione Injection, a 'First Time in India' formulation during 2012-13. It commissioned the production at Ankleshwar factory. During Financial Year 2013-14, the Company had floated a Wholly Owned Subsidiary Company namely Lyka Healthcare Limited to focus, develop and expand Domestic Marketing of Ethical Products. Its another subsidiary, Lyka Exports Limited reorganized its activities and resultant, it sold the Animal Healthcare Business in 2014. The subsidiaries, Lyka Healthcare Limited and Lyka Exports Limited merged with the Company which became effective from April 01, 2016. During the year 2021-22, IPCA together with persons acting in concert acquired 26.70% shares of the Company through Public Offer consisting a total shareholding of 27.76% of the Paid-up Equity Capital of the Company and resultant to acquisition in stake, became the Joint Promoters of Company.

Managing Director

KUNAL NARENDRA GANDHI

Founded

1976

NSE Symbol

LYKALABS

Lyka Labs Ltd Management

NameDesignation
KUNAL NARENDRA GANDHIChairman & MD & CEO
Sandeep P ParikhNon-Exec. & Independent Dir.
Yogesh B ShahExecutive Director & CFO
Dhara P. ShahNon-Exec. & Independent Dir.
Kishore P ShahCompany Sec. & Compli. Officer
Babulal JainIndependent Director
Prashant GodhaDirector
Shashil MendonsaDirector

Lyka Labs Ltd News

Lyka Labs to hold board meeting
On 21 May 2024
Lyka Labs to convene board meeting
On 16 April 2024
Lyka Labs reports consolidated net profit of Rs 1.78 crore in the December 2023 quarter
Sales rise 82.72% to Rs 32.56 crore
Lyka Labs to declare Quarterly Result
On 8 February 2024
Lyka Labs to conduct EGM
On 20 February 2024
Lyka Labs reports consolidated net loss of Rs 0.49 crore in the September 2023 quarter
Sales rise 9.64% to Rs 27.99 crore
Lyka Labs to hold board meeting
On 2 November 2023
Lyka Labs soars after receiving regulatory nod for
Lyka Labs jumped 4.48% to Rs 123.60 after the company announced the receipt of product permission from the Central Drugs Standard Control Organization of India to manufacture and market Tofacitinib Ointment (2% w/w).
Lyka Labs reports standalone net loss of Rs 1.72 crore in the June 2023 quarter
Sales decline 2.93% to Rs 21.24 crore
Lyka Labs reports consolidated net loss of Rs 1.85 crore in the June 2023 quarter
Sales decline 16.77% to Rs 22.88 crore

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
SUNPHARMA₹ 3,58,616 Cr
₹ 1,506.55
(0.80 %)
86.97
CIPLA₹ 1,09,708 Cr
₹ 1,339.55
(-1.42 %)
33.36
DIVISLAB₹ 1,00,611 Cr
₹ 3,793.50
(0.09 %)
73.75
DRREDDY₹ 98,044 Cr
₹ 5,921.00
(0.74 %)
22.59
ZYDUSLIFE₹ 97,423 Cr
₹ 982.15
(1.44 %)
36.23

Lyka Labs Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Lyka Labs Ltd shares in BlinkX

The share price of any stock is volatile and changes during the day due to a variety of variables. Lyka Labs Ltd's share price is ₹113.70 as of May 10, 2024

Lyka Labs Ltd's P/E ratio is 0.00 times as of May 10, 2024.

Lyka Labs Ltd's most recent financial reports indicate a price-to-book ratio of 5.76, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Lyka Labs Ltd's market is 393 Cr as on May 10, 2024.

The current financial records of Lyka Labs Ltd show a -12.34% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

The 52-week high/low price of a Lyka Labs Ltd stock is the highest and lowest price at which it has traded over that period (about one year) and is used as a technical indicator. Lyka Labs Ltd's 52-week high and low as of May 10, 2024 are ₹116.75 and ₹112.5 respectively.

As of the Apr 2024 quarter, the promoter shareholding in Lyka Labs Ltd stands at 58.10%. During the same period, Institutional Investors have shown a slight decrease in their holdings, dropping from 0.17% to 0.16%.